tetano
Editor, Senior Moderator
Cell Rep
. 2021 Jun 25;109385.
doi: 10.1016/j.celrep.2021.109385. Online ahead of print.
Resistance of SARS-CoV-2 variants to neutralization by antibodies induced in convalescent patients with COVID-19
Yu Kaku[SUP] 1 [/SUP], Takeo Kuwata[SUP] 2 [/SUP], Hasan Md Zahid[SUP] 1 [/SUP], Takao Hashiguchi[SUP] 3 [/SUP], Takeshi Noda[SUP] 4 [/SUP], Noriko Kuramoto[SUP] 1 [/SUP], Shashwata Biswas[SUP] 1 [/SUP], Kaho Matsumoto[SUP] 1 [/SUP], Mikiko Shimizu[SUP] 1 [/SUP], Yoko Kawanami[SUP] 1 [/SUP], Kazuya Shimura[SUP] 5 [/SUP], Chiho Onishi[SUP] 5 [/SUP], Yukiko Muramoto[SUP] 6 [/SUP], Tateki Suzuki[SUP] 7 [/SUP], Jiei Sasaki[SUP] 7 [/SUP], Yoji Nagasaki[SUP] 8 [/SUP], Rumi Minami[SUP] 9 [/SUP], Chihiro Motozono[SUP] 10 [/SUP], Mako Toyoda[SUP] 10 [/SUP], Hiroshi Takahashi[SUP] 11 [/SUP], Hiroto Kishi[SUP] 11 [/SUP], Kazuhiko Fujii[SUP] 11 [/SUP], Tsuneyuki Tatsuke[SUP] 12 [/SUP], Terumasa Ikeda[SUP] 13 [/SUP], Yosuke Maeda[SUP] 14 [/SUP], Takamasa Ueno[SUP] 10 [/SUP], Yoshio Koyanagi[SUP] 5 [/SUP], Hajime Iwagoe[SUP] 15 [/SUP], Shuzo Matsushita[SUP] 16 [/SUP]
Affiliations
Abstract
Administration of convalescent plasma or neutralizing monoclonal antibodies (mAbs) is a potent therapeutic option for coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. However, SARS-CoV-2 variants with mutations in the spike protein have emerged in many countries. To evaluate the efficacy of neutralizing antibodies induced in convalescent patients against emerging variants, we isolate anti-spike mAbs from two convalescent COVID-19 patients infected with prototypic SARS-CoV-2 by single-cell sorting of immunoglobulin-G-positive (IgG[SUP]+[/SUP]) memory B cells. Anti-spike antibody induction is robust in these patients, and five mAbs have potent neutralizing activities. The efficacy of most neutralizing mAbs and convalescent plasma samples is maintained against B.1.1.7 and mink cluster 5 variants but is significantly decreased against variants B.1.351 from South Africa and P.1 from Brazil. However, mAbs with a high affinity for the receptor-binding domain remain effective against these neutralization-resistant variants. Rapid spread of these variants significantly impacts antibody-based therapies and vaccine strategies against SARS-CoV-2.
Keywords: COVID-19; SARS-CoV-2; mAb; neutralizing antibody; variant.
. 2021 Jun 25;109385.
doi: 10.1016/j.celrep.2021.109385. Online ahead of print.
Resistance of SARS-CoV-2 variants to neutralization by antibodies induced in convalescent patients with COVID-19
Yu Kaku[SUP] 1 [/SUP], Takeo Kuwata[SUP] 2 [/SUP], Hasan Md Zahid[SUP] 1 [/SUP], Takao Hashiguchi[SUP] 3 [/SUP], Takeshi Noda[SUP] 4 [/SUP], Noriko Kuramoto[SUP] 1 [/SUP], Shashwata Biswas[SUP] 1 [/SUP], Kaho Matsumoto[SUP] 1 [/SUP], Mikiko Shimizu[SUP] 1 [/SUP], Yoko Kawanami[SUP] 1 [/SUP], Kazuya Shimura[SUP] 5 [/SUP], Chiho Onishi[SUP] 5 [/SUP], Yukiko Muramoto[SUP] 6 [/SUP], Tateki Suzuki[SUP] 7 [/SUP], Jiei Sasaki[SUP] 7 [/SUP], Yoji Nagasaki[SUP] 8 [/SUP], Rumi Minami[SUP] 9 [/SUP], Chihiro Motozono[SUP] 10 [/SUP], Mako Toyoda[SUP] 10 [/SUP], Hiroshi Takahashi[SUP] 11 [/SUP], Hiroto Kishi[SUP] 11 [/SUP], Kazuhiko Fujii[SUP] 11 [/SUP], Tsuneyuki Tatsuke[SUP] 12 [/SUP], Terumasa Ikeda[SUP] 13 [/SUP], Yosuke Maeda[SUP] 14 [/SUP], Takamasa Ueno[SUP] 10 [/SUP], Yoshio Koyanagi[SUP] 5 [/SUP], Hajime Iwagoe[SUP] 15 [/SUP], Shuzo Matsushita[SUP] 16 [/SUP]
Affiliations
- PMID: 34237284
- PMCID: PMC8226103
- DOI: 10.1016/j.celrep.2021.109385
Abstract
Administration of convalescent plasma or neutralizing monoclonal antibodies (mAbs) is a potent therapeutic option for coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. However, SARS-CoV-2 variants with mutations in the spike protein have emerged in many countries. To evaluate the efficacy of neutralizing antibodies induced in convalescent patients against emerging variants, we isolate anti-spike mAbs from two convalescent COVID-19 patients infected with prototypic SARS-CoV-2 by single-cell sorting of immunoglobulin-G-positive (IgG[SUP]+[/SUP]) memory B cells. Anti-spike antibody induction is robust in these patients, and five mAbs have potent neutralizing activities. The efficacy of most neutralizing mAbs and convalescent plasma samples is maintained against B.1.1.7 and mink cluster 5 variants but is significantly decreased against variants B.1.351 from South Africa and P.1 from Brazil. However, mAbs with a high affinity for the receptor-binding domain remain effective against these neutralization-resistant variants. Rapid spread of these variants significantly impacts antibody-based therapies and vaccine strategies against SARS-CoV-2.
Keywords: COVID-19; SARS-CoV-2; mAb; neutralizing antibody; variant.